Choosing a country will allow you to access local content and enable you to shop in your local currency.
In a world where late-stage failure during drug development can cost over $1 billion, foresight pays. And to see further, you have to look deeper.
Drug Discovery Suite is our portfolio of specialist technologies that allows you to achieve deeper insights at every stage of discovery, from target identification to lead optimization. Learn more about how these technologies fit into the drug discovery process.
Biacore systems measure molecular interactions in real-time using surface plasmon resonance (SPR). The SPR technology is label-free and facilitates detailed study of how lead compounds and antibodies bind to drug targets. Binding parameters such as affinity, kinetics, specificity, and selectivity are important in the selection of candidates with preferred properties.
” It’s like the difference between using a magnifying glass and a microscope. We’ll be able to see more and therefore understand more. ”
Dr. Per Källblad, CEO at Beactica
High-Content Analysis (HCA) can be defined as the automated extraction and analysis of quantitative data from images of cells captured with a high-resolution light microscope and sensitive camera. HCA can use multiple probes in a single assay and is performed on whole cells rather than cell extracts, leading to a deeper understanding of complex cellular mechanisms and interactions.
The benefits of HCA are especially relevant in drug discovery. Deeper insights into how a drug or compound acts in a functional context lead to more information and confidence in both hit selection and safety and efficacy, prior to lead candidate selection, while productivity advantages make HCA a valuable technology for target identification, for example through the use of RNAi screens.
” We used to use manual methods and simple instrumentation. They were labor intensive, time consuming, and didn't work very well. High content analysis has brought to us a method that works and is the only technology that has advanced predictive toxicology in a generation.”
Peter O’Brien, University College Dublin
In drug development, up to three quarters of toxicity problems are not detected until preclinical or later stages. Cardiotoxicity and hepatotoxicity are common causes of drug safety liabilities and withdrawal of drugs during development.
Cytiva Cardiomyocytes are derived from NIH-approved human embryonic stem (hES) cells and provide an abundant and reliable source of biologically-relevant cells for cardiac safety and toxicity testing. The availability of more biologically relevant and predictive assays and cell models is key to improving the success rate and reducing the cost of the drug discovery & development process. Such assays and models could facilitate the termination of unpromising compounds earlier in development and the engineering of potential drug molecules to remove toxic liabilities. Human embryonic stem cells have the potential to serve as an abundant & reliable source of differentiated cells for early safety screening.
Human embryonic stem
(hES) cells undergoing
stained for the pluripotency
marker Oct 4 (green)
and nuclei (blue).
GE Healthcare differentiated
cells are produced from
of pluripotent H7 hES cells,
shown here stained for the
pluripotency marker Oct 4
red) and nuclei (blue).
α-actinin (green) and
cardiomyocytes in a live
assay are stained with
probes that report nuclear
status (Hoechst 33342, blue),
potential (TMRM, red), calcium
mobilization (Fluo-4, green)
and plasma membrane
integrity (TOTO-3, not shown).
We've detected that you're using an unsupported browser.You may continue browsing, but for the best experience, please use Mozilla Firefox (v.30+), Google Chrome (v.35+) or Internet Explorer (v.11+).